William Blair analyst Brandon Vazquez has maintained their bullish stance on CBLL stock, giving a Buy rating on November 7.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brandon Vazquez has given his Buy rating due to a combination of factors that suggest Ceribell, Inc. is poised for significant growth. The company has only penetrated a small portion of its total addressable market, indicating substantial room for expansion. Additionally, Ceribell is enhancing its salesforce, which has grown by 57% since its IPO, to achieve full productivity, and is launching new products targeting neonate and pediatric segments, which could deepen existing account relationships and attract new ones.
Furthermore, Ceribell has secured a commitment from the Veterans Affairs (VA) to broaden its usage, and it is making strides in establishing treatment protocols for at-risk patient populations, which could further embed its solutions within existing accounts. With the stock price significantly lower than its peak last December, Vazquez sees this as an attractive entry point, especially given the company’s potential for both immediate and sustained growth. The shares are currently trading at three times the projected sales for 2026, reinforcing the Buy recommendation.
In another report released on November 7, BTIG also reiterated a Buy rating on the stock with a $30.00 price target.